Type to search

Mnemo Therapeutics Names Robert LaCaze as Chief Executive Officer | Pharmtech Focus
Research Demonstrates Novel HIT Receptor Enhances T Cell Antigen Sensitivity and Elicits Superior Tumor Control | Pharmtech Focus
Mnemo Therapeutics Announces €75 million Series A to Accelerate Next Generation Integrated CAR-T and Epigenetic Targeting Platform | Pharmtech Focus